Reported 1 day ago
AbbVie, a leading biopharmaceutical company known for its robust dividend history, has seen its stock price soar following an extension of the exclusivity period for its immunology drug Rinvoq, reaching record highs. With a significant rise in revenue and a strong growth outlook driven by key products like Rinvoq and Skyrizi, analysts maintain a positive view on AbbVie. Despite some challenges affecting earnings, the consensus rating remains a 'Moderate Buy,' suggesting that AbbVie is still a solid investment choice for those seeking reliable returns in the pharmaceutical sector.
Source: YAHOO